Emapalumab Biosimilar Antibody

Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody used for the treatment of hemophagocytic lymphohistiocytosis (HLH).

The HLH condition is a hyperinflammatory status characterized by the overwhelming activation of normal T lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death. Emapalumab acts by binding and neutralizing interferon-gamma. The specific interaction between Emapalumab and interferon-gamma produces an inhibition in the interaction between interferon-gamma and its cognate receptor on T-cells. Emapalumab can inhibit both free and IFNGR1-bound interferon-gamma as well as the interaction with IFNGR1 and IFNGR2 on the cell surface.